Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-622 · 1 trial · 1 indication
Occurrence and incidence of Treatment-Emergent Adverse Events (TEAE) and serious adverse events during the study.
| Arm | Type | Description |
|---|---|---|
| CDX-622 | EXPERIMENTAL | Eligible participants will receive a single dose |
| Name | Type | Description |
|---|---|---|
| CDX-622 | DRUG | Administered Intravenously |
Key Inclusion Criteria: 1. Males and females, ≥ 18 years of age 2. Diagnosis of mild to moderate asthma for at least 12 months 3. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal 4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1 5. Both males and f...
CDX-622 is an investigational small molecule being developed for the treatment of mild to moderate asthma. It is currently in Phase 1 clinical development and is not approved for any indication. Celldex Therapeutics is evaluating it in adults with mild to moderate asthma in the United States.
CDX-622 targets TSLP, also known as thymic stromal lymphopoietin. TSLP is a cytokine involved in airway inflammation. By targeting TSLP, CDX-622 is designed to interfere with inflammatory signaling relevant to asthma. It is a small molecule administered as an investigational therapy.
CDX-622 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company that trades under the ticker symbol CLDX. Celldex is the sponsor of the ongoing Phase 1 study of CDX-622 in participants with mild to moderate asthma.
CDX-622 is in Phase 1 clinical development. The only listed trial is a Phase 1 study that is currently recruiting participants. CDX-622 is investigational and has not been approved by the FDA for any use.
CDX-622 is being studied in one clinical trial, NCT07330778, titled A Study of CDX-622 in Participants With Mild to Moderate Asthma. The trial is a Phase 1, uncontrolled study recruiting 12 participants aged 18 years and older in the United States. It is currently active and recruiting.